SCHEDULE: Insider Reduces Calidi Biotherapeutics Stake to 0.3%

Ognian Anguelov Gavrilov has reduced his beneficial ownership in Calidi Biotherapeutics, Inc. to 0.3% of outstanding common stock.

Summary

• Ognian Anguelov Gavrilov, Managing Partner at Gavrilov & Brooks, has reported a disposition of shares in Calidi Biotherapeutics, Inc.
• Following these dispositions, Mr. Gavrilov beneficially owns 20,000 shares of Common Stock, representing approximately 0.3% of the outstanding class.
• Mr. Gavrilov retains sole voting and sole dispositive power over these 20,000 shares.
• The reporting person does not currently have plans for actions described in Item 4 of Schedule 13D, but may acquire or dispose of securities in the future based on market conditions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development due to an insider reducing their stake, though the resulting ownership percentage is small and the filing provides no specific negative rationale for the disposition.

Negatives

• An insider, Ognian Anguelov Gavrilov, has effected dispositions of shares, reducing his beneficial ownership in Calidi Biotherapeutics, Inc. to 0.3% of the outstanding common stock.

Future Outlook

The reporting person may, from time to time, acquire or dispose of securities of Calidi Biotherapeutics, Inc. in the open market or otherwise, depending on market conditions and other factors.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for transparency regarding significant ownership changes by individuals or groups, often signaling shifts in investor sentiment or strategic intent. While this filing indicates a disposition by an individual, the resulting 0.3% stake is relatively small, suggesting a portfolio adjustment rather than a major strategic move.

Stakeholder Impact

• Shareholders may note the reduction in beneficial ownership by an individual associated with the company, which could be interpreted as a minor signal regarding insider sentiment.

Next Steps

• The reporting person may acquire or dispose of additional securities of the Issuer in the future.

Key Dates

Recommendation

The filing details an insider's disposition of shares, resulting in a 0.3% beneficial ownership. While a disposition is generally not a positive signal, the small percentage and lack of further context or stated negative intent mean this filing alone does not warrant a strong 'sell' recommendation. Investors should 'hold' and monitor for further developments or more substantial insider activity.

Keywords

Calidi Biotherapeutics, Schedule 13D, Insider Trading, Stock Ownership, Biotechnology, Common Stock, Gavrilov Ognian Anguelov